Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | GRM5 | P41594 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596314 | 0.90 | GRM5 (0.58) | GRM5MEN1KMT2A | |
| SCHEMBL3588802 | 0.89 | KDR (0.53) | KDRSMN1; SMN2RAF1TEKMEN1 | |
| SCHEMBL6017011 | 0.87 | FAAH (0.51) | KDRSMN1; SMN2RAF1KDM1ARCOR1 | |
| SCHEMBL3589751 | 0.85 | KDR (0.53) | KDRRAF1BRAFTEK | |
| SCHEMBL3593695 | 0.83 | ALDH1A1 (0.55) | KDRGRM5SMN1; SMN2KMT2A | |
| SCHEMBL3602119 | 0.83 | KDR (0.49) | KDRRAF1BRAFTEKMEN1 | |
| SCHEMBL30912925 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2MEN1KMT2ANHERF1 | |
| SCHEMBL30642989 | 0.79 | GRIK1 (0.48) | GRM5MEN1KMT2ANHERF1 | |
| SCHEMBL29086861 | 0.79 | GRIK1 (0.48) | GRM5MEN1KMT2ANHERF1 | |
| SCHEMBL3591965 | 0.79 | RAF1 (0.47) | KDRSMN1; SMN2RAF1KDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643991-B1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-7691870-B2 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| EP-1643991-A1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005004863-A1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | BRAF, RAF1, ARAF | KDR 843/4885GRM5 3847/4885SMN1; SMN2 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.